Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$1.89 +8.0%	$2.46	$0.55 ▼ $6.19	$148.12M	3	1.27 million shs	364,701 shs
FATE Fate Therapeutics	$1.09 -5.7%	$1.13	$0.66 ▼ $4.20	$125.13M	2.24	2.04 million shs	2.13 million shs
HURA TuHURA Biosciences	$2.95 -9.1%	$2.62	$1.80 ▼ $8.40	$147.39M	0.04	307,843 shs	207,030 shs
RNXT RenovoRx	$0.90 -4.4%	$1.24	$0.75 ▼ $1.69	$32.95M	1.26	157,382 shs	139,378 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	0.00%	+3.55%	-11.17%	+92.31%	-6.42%
FATE Fate Therapeutics	0.00%	+5.50%	-7.26%	-0.86%	-70.05%
HURA TuHURA Biosciences	0.00%	+6.21%	+14.04%	+14.84%	+324,999,900.00%
RNXT RenovoRx	0.00%	-1.59%	-25.96%	-20.98%	-6.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTOR Citius Oncology	1.3456 of 5 stars	3.0	0.0	0.0	1.8	1.7	0.0
FATE Fate Therapeutics	3.9875 of 5 stars	3.1	2.0	4.7	2.0	2.5	0.6
HURA TuHURA Biosciences	1.4755 of 5 stars	3.7	0.0	0.0	1.9	0.0	0.0
RNXT RenovoRx	2.8794 of 5 stars	3.5	5.0	0.0	2.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	58.73% Upside
FATE Fate Therapeutics	2.14	Hold	$3.30	204.15% Upside
HURA TuHURA Biosciences	3.40	Buy	$12.67	328.80% Upside
RNXT RenovoRx	3.00	Buy	$7.25	706.45% Upside

Current Analyst Ratings Breakdown

Latest RNXT, CTOR, FATE, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A
FATE Fate Therapeutics	$8.47M	14.77	N/A	N/A	$2.80 per share	0.39
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
RNXT RenovoRx	$40K	823.71	N/A	N/A	$0.19 per share	4.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
FATE Fate Therapeutics	-$186.26M	-$1.45	N/A	N/A	N/A	-2,025.05%	-50.95%	-36.76%	11/11/2025 (Estimated)
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	-248.79%	-150.83%	10/6/2025 (Estimated)
RNXT RenovoRx	-$8.81M	-$0.38	N/A	N/A	N/A	N/A	-120.68%	-89.23%	11/12/2025 (Estimated)

Latest RNXT, CTOR, FATE, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HURA TuHURA Biosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
8/14/2025	Q2 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.25 million	$0.42 million
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.12	0.35	0.02
FATE Fate Therapeutics	N/A	8.04	8.04
HURA TuHURA Biosciences	N/A	0.83	0.83
RNXT RenovoRx	N/A	8.61	8.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
FATE Fate Therapeutics	97.54%
HURA TuHURA Biosciences	0.62%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
FATE Fate Therapeutics	5.51%
HURA TuHURA Biosciences	0.20%
RNXT RenovoRx	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
FATE Fate Therapeutics	550	115.33 million	108.98 million	Optionable
HURA TuHURA Biosciences	N/A	50.05 million	49.95 million	N/A
RNXT RenovoRx	6	36.65 million	33.30 million	Not Optionable

RNXT, CTOR, FATE, and HURA Headlines

Recent News About These Companies

RenovoRx (NASDAQ:RNXT) Upgraded by Wall Street Zen to Hold Rating

August 23 at 2:09 AM | americanbankingnews.com

Discovering the Next Wave of Biotech Innovation (MDCX, RNXT, JSPR, LSB)

August 22 at 8:38 AM | theglobeandmail.com

FY2025 EPS Estimates for RenovoRx Increased by HC Wainwright

August 22 at 2:01 AM | americanbankingnews.com

FY2027 EPS Estimates for RenovoRx Cut by HC Wainwright

August 21, 2025 | americanbankingnews.com

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025

August 20, 2025 | finance.yahoo.com

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

August 20, 2025 | businesswire.com

RenovoRx, Inc. (NASDAQ:RNXT) Q2 2025 Earnings Call Transcript

August 19, 2025 | msn.com

RenovoRx Revenue Jumps 28 Percent in Q2

August 14, 2025 | theglobeandmail.com

RenovoRx Reports Strong Q2 2025 Revenue Growth

August 14, 2025 | msn.com

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates

August 14, 2025 | zacks.com

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

August 14, 2025 | businesswire.com

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

August 6, 2025 | globenewswire.com

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

July 28, 2025 | finance.yahoo.com

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

July 14, 2025 | businesswire.com

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of Stock

June 10, 2025 | insidertrades.com

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

June 6, 2025 | finance.yahoo.com

Ascendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€

June 5, 2025 | fr.investing.com

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations

May 17, 2025 | investing.com

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

May 16, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNXT, CTOR, FATE, and HURA Company Descriptions

Citius Oncology NASDAQ:CTOR

$1.89 +0.14 (+8.00%)

Closing price 03:59 PM Eastern

Extended Trading

$1.88 0.00 (-0.26%)

As of 04:04 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Fate Therapeutics NASDAQ:FATE

$1.08 -0.07 (-5.65%)

Closing price 03:59 PM Eastern

Extended Trading

$1.13 +0.04 (+4.15%)

As of 04:04 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

TuHURA Biosciences NASDAQ:HURA

$2.95 -0.30 (-9.11%)

Closing price 03:59 PM Eastern

Extended Trading

$3.02 +0.07 (+2.23%)

As of 04:04 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

RenovoRx NASDAQ:RNXT

$0.90 -0.04 (-4.39%)

Closing price 03:56 PM Eastern

Extended Trading

$0.90 0.00 (-0.22%)

As of 04:04 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time